Hispanic, blacks and women have been disproportionately affected by the AIDS epidemic. Despite increased burden of AIDS cases in these minority populations, access to clinical trials remain low. Puerto Rico (P.R.) ranks second, within all states and territories, in AIDS cases per 100,000 (51.4). AIDS is the leading cause of death for the 20-40 age range group. During the past 5 years, highly significant increments in heterosexual transmission and infection in women have been demonstrated. During the past 3 years we have identified and developed all the necessary infrastructure components for the establishment of an ACTU at the U.P.R., School Medicine. This effort has matured into a research unit with excellent facilities, key research staff, ancillary services and community participation. During our last 6 months we were allowed to enroll patients in ACTG 175. In a 3 month period we evaluated 65 candidates and accrued 16 from all risks behavior groups. As of Dec., 1992, a total of 112 follow-up visits had been recorded with only one missed appointment (visit completion rate of 99%). Only 1 patient was discontinued because of poor compliance and two patients were able to maintain their participation in the protocol by successfully transferring them to ACTU's in USA. It is then, imperative, that an adult ACTU in P.R. be available as a research tool and as a much needed therapeutic alternative.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI034832-02
Application #
2070031
Study Section
Special Emphasis Panel (SRC (49))
Project Start
1993-09-01
Project End
1997-08-31
Budget Start
1994-09-01
Budget End
1995-08-31
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Puerto Rico Med Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
San Juan
State
PR
Country
United States
Zip Code
00936
Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Sattler, Fred R; Rajicic, Natasa; Mulligan, Kathleen et al. (2008) Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial. Am J Clin Nutr 88:1313-21
Twigg Iii, Homer L; Weiden, Michael; Valentine, Fred et al. (2008) Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis 197:109-16
Gulick, Roy M; Lalama, Christina M; Ribaudo, Heather J et al. (2007) Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS 21:813-23
Shikuma, Cecilia M; Yang, Yang; Glesby, Marshall J et al. (2007) Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 44:540-50
Bosch, Ronald J; Bennett, Kara; Collier, Ann C et al. (2007) Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr 44:268-77
Mulligan, Kathleen; Parker, Robert A; Komarow, Lauren et al. (2006) Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 41:590-7
Benson, Constance A; Vaida, Florin; Havlir, Diane V et al. (2006) A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. J Infect Dis 194:1309-18
Aweeka, Francesca T; Rosenkranz, Susan L; Segal, Yoninah et al. (2006) The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine. AIDS 20:1833-41

Showing the most recent 10 out of 23 publications